Sp17 (C17) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-Sp17 (C17) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Sp17 (C17) |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | human |
| Isotype | n/a |
| Format | unconjugated |
| Size | 0.2 mg |
| Concentration | 0.200 mg/ml |
| Applications | Western Blot (WB) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: Human Sp17. The highly immunogenic cancer-testis antigen Sp17 was originally thought to be expressed exclusively in the testis with the primary function of binding the extra cellular matrix of the oocyte (1,2). Upon further investigation Sp17 was found to be expressed by tumor cells with multiple myeloma in up to 30% of the cases studied (3,4). Sp17 has three functional domains, N-terminal, central, and C-terminal domains. The N-terminal domain contains an A-kinase anchoring protein binding motif. The central domain is necessary for heparin binding and the C-terminal domain contains a calmodulin-binding domain (1&2). |
| Immunogen | Immunogen: Synthetic peptide mapping to the carboxy terminal domain of human Sp17. |
| Other Names | n/a |
| Gene, Accession # | [Sp17] |
| Catalog # | MBS440065 |
| Price | $240 |
| Order / More Info | Sp17 (C17) Antibody from MYBIOSOURCE INC. |
| Product Specific References | 1. Wen Y, Richardson RT, Widgren EE, O?Rand MG. 2001. Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J. 357(Pt1):25-31.2. Frayne J, Hall L. 2002. A re-evaluation of sperm protein 17 (Sp17) indicates a regulatory role in an A-kinase anchoring protein complex, rather than a unique role in sperm pellucida binding. Reproduction 124(6):767-774.3. Chiriva-Internati M, Wang Z, Salati E, Wroblewski D, Lim SH. 2002. Succuessful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantion for Sp17-positive multiple myeloma. Scand J Immunology 56(4):429-433.4. Chiriva-Internati M, Wang Z, Xue Y, Bumm K, Hahn AB, Lim SH. 2001. Sperm protein (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk. Eur J Immunology 31(8):2277-2283. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies